Top Markets
Coin of the day
Spectral Medical Inc. Spectral Medical Inc.

Spectral Medical Inc.

EDT
Clasificación en acciones #16678
Spectral Medical Inc. focuses on the development and commercialization of... Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, Russia, and internationally. The company markets Endotoxin Activity Assay, a rapid in-vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B-Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops, manufactures, and markets monoclonal and polyclonal antibodies, recombinant cardiac proteins, antibodies, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.
Precio por acción
$0.95411796
Última sincronización: 2026-09-01
Capitalización bursátil
$279.96M
Cambio (1 día)
-0.76%
Cambio (1 año)
-16.23%
País
CA
Comercio Spectral Medical Inc. (EDT)

Categoría

Ingresos de Spectral Medical Inc. (EDT)
Ingresos en Sep 2026 TTM: 0
Según los últimos informes financieros de Spectral Medical Inc., los ingresos actuales de la empresa (TTM) son 0. En 2026, la empresa obtuvo unos ingresos de 0 igual a los ingresos del año 2026, que fueron de 0. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Spectral Medical Inc. desde 2026 hasta 2026
Ingresos al final de cada año
Año Ingresos Cambiar
Not enough data for the provided dates.
Ingresos de empresas similares o competidoras
Empresa Ingresos Diferencia de ingresos País
$46.34B -
US
$25.11B -
US
- -
CN
$2.71B -
US
$4.55B -
US